Citations

Clear

1828 citation(s) found for "Su, Emily".

Addressing the needs of nano-rare patients: the n-Lorem experience
Crooke, Stanley T. , Glass, Sarah, Gleeson, Joseph G, Mignon, Laurence, Skourti-Stathaki, Konstantina , Douville, Julie , Knutsen, Megan, Pu, He, Bain, Jennifer M, Berry-Kravis, Elizabeth , Kim-McManus, Olivia, Eichler, Florian , Chung, Wendy K, Nagy, Amanda, Kaufmann, Horacio, Gonzalez-Duarte, Alejandra, Oskarsson, Björn, McCourt, Emily A. , Berry‐Kravis, Elizabeth , Nagy, Amanda , Leung, Nelson , Kaufmann, Horacio , Gleeson, Joseph G. , Mignon, Laurence, Bain, Jennifer , Shneider, Neil A. , McManus, Olivia Kim , Chung, Wendy K. , González-Duarte, Alejandra

Mayo Clinic

Nucleic Acids Research | May 8, 2026 | Volume: 54 | Issue: 10 | Pages: No page available

10.1093/nar/gkag504 | PMID 42227334 Get It

Abstract Patients with extremely rare pathogenic variants pose unique challenges to current healthcare systems. Nano-rare mutations have been defined as mutations with a known prevalence of <30 patients worldwide, but because of the small fraction of humans who have undergone genetic testing, neither the precise prevalence of individual mutations nor the total prevalence of patients with nano-rare mutations is known. n-Lorem is a non-profit founded in 2020 with the mission of equitably discovering, developing, and providing bespoke experimental antisense oligonucleotides (ASOs) for free, for life, to patients with nano-rare mutations that are amenable to ASO treatment. In this perspective, we provide an overview of the n-Lorem processes and systems, the characteristics of the first 329 patients who have applied for treatment for whom initial assessment was completed and suitability for ASO treatment determined, and a summary of the results of ASO treatment for patients treated to date. Detailed data on individual patients and the overall clinical safety and tolerability profiles of the ASOs for which there are clinical data are the subjects of other manuscripts.
Web-Based Amblyopia Decision Support Tool
Summers, Allison I. , Hatch, S.W., Wiecek, Emily , Hribar, Michelle R. , Robinson, Julianne L., Chen, Angela M., Kulp, Marjean T., Chen, Debora M. Lee, Repka, Michael X., Roberts, Tawna L. , Wallace, David K. , Vricella, Marilyn, Chang, Steven, Stutz, Kathleen M., Beaulieu, Wesley T., Kraker, Raymond T., Cotter, Susan A., Holmes, Jonathan M., Weise, Katherine K., Pineles, Stacy L., (PEDIG), Pediatric Eye Disease Investigator Group, Hatt, Sarah R. , Chen, Angela M. , Kulp, Marjean Taylor , Repka, Michael X. , Wang, Jingyun, Beaulieu, Wesley T , Kraker, Raymond T. , Cotter, Susan A. , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | May 7, 2026 | Volume: 144 | Issue: 6 | Pages: 545

10.1001/jamaophthalmol.2026.1095 | PMID 42096234 Get It

Importance Amblyopia is the leading cause of monocular decreased best-corrected vision in children. Early detection and intervention are key for optimal treatment outcomes; however, limited access to pediatric eye specialists may hinder timely care and affect visual outcomes. Given the shortage of specialty-trained eye care professionals in the US, there is need to support comprehensive eye care professionals who are willing to examine and treat children with amblyopia. Objective A panel from the Pediatric Eye Disease Investigator Group synthesized relevant literature and incorporated consensus opinion where direct evidence was lacking to create the Amblyopia Navigator Decision-Support Instrument, a free, web-based amblyopia decision support tool for eye care professionals. Evidence Review The decisions related to optimal diagnostic measures, pass/refer criteria, and management recommendations were informed by 147 publications. In areas where direct evidence was lacking, guidance was supplemented with clinical trial protocols or existing professional guidelines. When data were conflicting or unavailable, recommendations were established through committee consensus. A single reviewer independently performed standardized (though not systematic) literature reviews to avoid missing pertinent recent publications. Findings Presented are the process used, supporting evidence, and recommendations for testing methods, refractive correction, amblyopia treatment options, treatment adjustments, and monitoring schedules. Conclusions and Relevance Because amblyopia is common and typically responds well to treatment, decision support tools that optimize its management could increase access to pediatric eye care by facilitating earlier detection, enabling broader participation of primary eye care professionals, and ultimately improving visual outcomes. Through this work and the development of the forthcoming free, web-based application version, Amblyopia Navigator Decision-Support Instrument, the Pediatric Eye Disease Investigator Group has created decision support tools designed to assist optometrists and ophthalmologists in the care of children aged 3 to 17 years with amblyopia.
Cost‐Effectiveness of Control‐ IQ + Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States
Rawashdh, Neda Al, Patel, Bimal V. , Wang, Sharon M., Zur, Richard M., Anaya, Pablo, Pinsker, Jordan E., Sasson-Katchalski, Ravid, Trahan, Alex C., Assadi, Kimia, Kudva, Yogish C., Beck, Roy W., Al Rawashdh, Neda , Messer, Laurel H , Zur, Richard M. , Kahn, Emily B. , Pinsker, Jordan E. , Trahan, Alex C., Kudva, Yogish C. , Beck, Roy W.

Mayo Clinic

Diabetes, Obesity and Metabolism | May 6, 2026 | Volume: 28 | Issue: 7 | Pages: 6280-6290

10.1111/dom.70759 | PMID 42086278 Get It

ABSTRACT Objective Automated insulin delivery (AID) has been established as an effective therapy for individuals with type 1 diabetes. This analysis evaluates the clinical and economic outcomes of AID compared with multiple daily injections plus continuous glucose monitoring (MDI/CGM) in adults with type 2 diabetes. Materials and Methods The IQVIA CORE Diabetes Model v10.0 was employed to simulate the impact of using the t:slim X2 insulin pump with Control‐IQ+ technology (Control‐IQ+) versus MDI/CGM over a 50‐year period using data from the 2IQP randomized controlled trial (NCT05785832). Trial data informed cohort demographics, intervention effects and resource utilization while literature sources provided health state utilities and costs. Scenario analyses examined the effect of Control‐IQ+ on reducing HbA1c based on alternative HbA1c progression estimates from the Swedish National Diabetes Registry and alternative resource use and treatment effects from real‐world evidence. Results The base case analysis indicated that direct medical costs per individual for type 2 diabetes management with Control‐IQ+ were $239 935 compared to $209 792 with MDI/CGM use. Control‐IQ+ resulted in 0.51 additional quality‐adjusted life years (QALYs: 10.36 vs. 9.85 for MDI/CGM), yielding an incremental cost‐effectiveness ratio (ICER) of $59 417 per QALY, 95% CI: ($55 836, $62 998). In probabilistic sensitivity analyses, 89% of simulations produced ICERs below $100 000/QALY. ICERs across all scenarios remained below $100 000 per QALY. Conclusions Control‐IQ+ is associated with increased life expectancy, higher QALYs and reduced complication rates. These findings suggest that Control‐IQ+ is cost‐effective relative to MDI/CGM for managing patients with type 2 diabetes in the United States.
Real-World Analysis of Adverse Events in Patients With Triple-Negative Breast Cancer Receiving Therapy per KEYNOTE-522
Hofherr, Mara, Davis, Andrew A. , January, Spenser E. , Raheem, Farah , Lyons, Lauren , Hsin, Jerline , Kraft, Shawna , Schepers, Allison , Taraba, Jodi L. , Blazawski, Jon , Bohnenkamp, Colleen, Hummert, Shelly, Grate, Lisa , Keisner, S. V., Hobbs, Jacob , Davis, Todd , White, Traci, Sandhu, Avneek Singh, Boulbol, Fouad, Finch, Kelsey , Fahey, Olivia , Resnick, Yonatan , Harwood, K., Armgardt, Emily, Mazewski, Douglas, Svoboda, Alison, Keegan, Aimee , Yu, Wai, Watson-Rose, Meredith, Madden, Katherine, Upton, Charlie, Mina, Lida, Owen, Emily , Clifton, Katherine , Hofherr, Mara Lacy , January, Spenser , Schepers, Allison J , Taraba, Jodi L , Keisner, Sidney V , Harwood, Kayla, Owen, Emily J , Clifton, Katherine , Raheem, Farah , Kraft, Shawna , Hummert, Shelly, Grate, Lisa , Madden, Katherine, Karikalan, Suganya Arunachalam

Mayo Clinic

JCO Oncology Practice | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-24-00819 | PMID 42085641 Get It

PURPOSE Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Early-stage, high-risk patients with TNBC are treated with chemotherapy and pembrolizumab per the KEYNOTE-522 regimen. This report examines real-world clinical effectiveness and toxicity of this regimen. METHODS This 19-site retrospective analysis included all patients who received at least one dose of the KEYNOTE-522 regimen. Safety, efficacy, and health care encounters were collected. RESULTS 675 patients from 19 sites in the United States who received chemotherapy and pembrolizumab for early-stage TNBC were included. 547 (81.0%) patients underwent surgery and 250 (54.7%) patients had a pathologic complete response (pCR). No baseline characteristics were predictive of pCR status. 224 patients (33.2%) had an adverse drug event resulting in ≥1 dose reduction of chemotherapy and were significantly more likely to have residual disease. Immune-related adverse events (irAEs) were observed in 388 (57.5%) patients and grade 3+ irAEs were observed in 176 (26.1%) patients. There was no difference in pCR status between provider's choice chemotherapy schedules. There was no difference of pCR rate between Black and White patients (55.6% v 51.6%, P = .489). White patients were significantly more likely to have any grade and grade 3+ irAEs. Older patients (age ≥65 years) had similar pCR rates compared with younger patients; however, older patients were significantly more likely to have grade 3+ irAEs. CONCLUSIONS In this multi-institutional real-world cohort, we observed a lower pCR rate, higher rates of toxicity, frequent emergency health care utilization, and the reporting of rare irAEs at higher frequency than the KEYNOTE-522 regimen. These findings have important implications for clinical management of patients with early-stage TNBC and warrant further validation with real-world data sets.
Extracorporeal Membrane Oxygenation for Pneumocystis Pneumonia: Outcomes in Patients From the Extracorporeal Life Support Organization
Henry, Kyle J., Ham, Kealy, Cartin-Ceba, Rodrigo, Khattar, Georges , D’Cunha, Jonathan, Sen, Ayan, Patel, Bhavesh, Pulsipher, Aaron M. , Thompson, Emily , Thompson, Emily R , D'Cunha, Jonathan, Pulsipher, Aaron M , Thompson, Emily R., Vikram, Holenarasipur R. , Cartin‐Ceba, Rodrigo , Limper, Andrew H.

Mayo Clinic

Critical Care Explorations | May 5, 2026 | Volume: 8 | Issue: 5 | Pages: e1414

10.1097/cce.0000000000001414 | PMID 42084230 Get It

OBJECTIVES: Pneumocystis jirovecii pneumonia (PCP) can cause severe hypoxemic respiratory failure in immunocompromised patients. Contemporary outcomes of venovenous extracorporeal membrane oxygenation (VV ECMO) support for PCP are poorly characterized, and existing reports are limited to small case series. DESIGN: Retrospective cohort study. SETTING: International registry study using the Extracorporeal Life Support Organization (ELSO) registry. PATIENTS/SUBJECTS: Adults with PCP-associated hypoxemic respiratory failure supported with VV ECMO between 2011 and 2024. INTERVENTIONS: VV ECMO. MEASUREMENTS AND MAIN RESULTS: A total of 209 patients with PCP-associated respiratory failure supported with VV ECMO were identified. The overall in-hospital mortality was 60.8%. Survivors were younger than nonsurvivors (median age 41.9 vs. 46.8 yr; p = 0.047). Duration of mechanical ventilation before VV ECMO was longer among nonsurvivors (median 4.7 vs. 1.6 d; p = 0.019). The proportion of patients with HIV infection was similar among survivors and nonsurvivors (19.5% vs. 22.1%; p = 0.73). Pre-ECMO vasopressor use, prone positioning, and renal replacement therapy were common and did not differ between groups. Clinical course was characterized by prolonged VV ECMO support (median 18.6 d) and frequent complications, including pneumothorax (21.1%), renal replacement therapy during VV ECMO (31.6%), intracranial hemorrhage or stroke (7.7%), and major pulmonary or gastrointestinal hemorrhage (16.8%). PCP accounted for a small proportion of VV ECMO runs reported to the ELSO registry throughout the study period at 0.36% of reported cases. No significant temporal trend in mortality was observed. CONCLUSIONS: PCP-associated respiratory failure supported with VV ECMO is associated with substantial mortality and prolonged VV ECMO support. These findings provide contemporary benchmarks that may inform VV ECMO candidacy discussions and expectations in this challenging patient population.
Criterion and convergent validity of plasma biomarkers in early‐onset Alzheimer's disease: Initial findings from LEADS
Hammers, Dustin B., Polsinelli, Angelina, Eloyan, Ani, Taurone, Alexander, Thangarajah, Maryanne, Foroud, Tatiana, Gao, Sujuan, Beckett, Laurel, Joie, Renaud La, Touroutoglou, Alexandra, Vemuri, Prashanthi, Zetterberg, Henrik, Blennow, Kaj, Nemes, Sára , Костадинова, Ралица, Aisen, Paul, Nudelman, Kelly N., Kirby, Kala, Atri, Alireza, Clark, David, Day, Gregory S., Duara, Ranjan, Graff‐Radford, Neill R., Grant, Ian, Honig, Lawrence S., Johnson, Erik C. B., Jones, David T., Masdeu, Joseph C., Mendez, Mario F., Parand, Leila, Womack, Kyle, Musiek, Erik, Onyike, Chiadi U., Riddle, Meghan, Rogalskı, Emily , Salloway, Stephen, Sha, Sharon J., Turner, Raymond Scott, Wingo, Thomas S., Wolk, David A., Carrillo, Maria C., Rabinovici, Gil D., Dickerson, Bradford C., Dage, Jeffrey L., Apostolova, Liana G., Carrillo, María C. , Rabinovici, Gil D. , Joie, Renaud La , Polsinelli, Angelina J. , La Joie, Renaud , Rabinovici, Gil D , Hammers, Dustin B , Eloyan, Ani , Taurone, Alexander, Thangarajah, Maryanne, Foroud, Tatiana , Gao, Sujuan , Beckett, Laurel , Touroutoglou, Alexandra , Vemuri, Prashanthi , Zetterberg, Henrik , Blennow, Kaj , Kostadinova, Ralitsa, Aisen, Paul , Nudelman, Kelly , Kirby, Kala, Atri, Alireza , Clark, David, Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Johnson, Erik C. B. , Jones, David T. , Masdeu, Joseph C , Mendez, Mario F. , Womack, Kyle , Musiek, Erik , Onyike, Chiadi U. , Riddle, Meghan , Salloway, Stephen , Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S , Wolk, David A. , Dickerson, Bradford Clark , Dage, Jeffrey L. , Apostolova, Liana G.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | May 4, 2026 | Volume: 18 | Issue: 2 | Pages: No page available

10.1002/dad2.70342 | PMID 42088846 Get It

Abstract INTRODUCTION : Despite expanding use of plasma biomarkers for Alzheimer's disease (AD), minimal examination has been undertaken in early‐onset AD (EOAD). Prior analyses assessed criterion and convergent validity of common plasma biomarkers in a well‐characterized sample with sporadic EOAD. METHODS : Plasma amyloid beta (Aβ) 42/40, tau phosphorylated at threonine 231 (p‐tau231), glial fibrillary acidic protein (GFAP), and neurofilament light change (NfL) levels were obtained for 189 EOAD, 52 early‐onset non‐AD (EOnonAD), and 83 cognitively normal (CN) participants. Diagnostic group differences, convergence with imaging biomarkers, and the capacity to predict specific cognitive domains were investigated. RESULTS : After controlling for cognitive status, EOAD participants exhibited more pathologic levels of Aβ42/40, p‐tau231, and GFAP relative to EOnonAD participants. However, NfL displayed the greatest sensitivity to non‐amnestic cognitive impairment across the sample. DISCUSSION : These results establish criterion and convergent validity of plasma biomarkers in sporadic EOAD and highlight complementary roles that AD‐specific and non‐specific plasma markers may play across the course of AD care.
Antibiotic Duration After Debridement and Implant Retention for Early Postoperative Spinal Implant Infections: A Multicenter Cohort Study
Tai, Don Bambino Geno, O'Neil, Jessica C, Nelson, Sandra B. , Tande, Aaron J. , Corvino, Daniela De Lima, Ritter, Alaina S , Aronson, Jenny, Certain, Laura, Furukawa, Daisuke, Abdalla, Tarek , Fleece, Molly , Tobert, Daniel G, Erickson, Melissa, Seidelman, Jessica, Team, SPIRIT, Chan, Julie L, Chalouhi, Nohra , Decker, Matthew , Hoh, Daniel J. , Manohar, Tanvi, Murad, Gregory, Roth, Steven G. , O'Neil, J , Tai, Don Bambino Geno , Nelson, Sandra B , Tande, Aaron , Corvino, Daniela De Lima , Ritter, Alaina S , Aronson, Jenny , Furukawa, Daisuke , Tatara, Alexander M , Green, Cynthia L , Tobert, Daniel G , Seidelman, Jessica , Tai, Don Bambino Geno , Poehlein, Emily , O’Neil, Jessica C , Certain, Laura , Erickson, Melissa M , Chan, Julie L.

Mayo Clinic

Clinical Infectious Diseases | May 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag300 | PMID 42084484 Get It

Abstract Background Postoperative spinal implant infections (PSIIs) are a serious complication of instrumented spinal fusion. Although debridement with implant retention is standard for early infection, the optimal duration of antimicrobial therapy remains uncertain. Methods We conducted a multicenter retrospective cohort study across 10 US academic centers, including adults with early PSII (≤90 days after fusion surgery) from 2017 to 2021. We excluded patients who experienced treatment failure within 6 weeks of debridement. The primary outcome was treatment failure. Antibiotic therapy effect was analyzed as a time-varying exposure using adjusted Cox proportional hazards models. Secondary analyses included 12-week landmark and clone-censor-weighted models to compare durations ≤ 12 weeks versus >12 weeks. Results A total of 116 patients out of 499 (23.2%) experienced treatment failure during a median follow-up of 3.2 years. Among patients who remain failure-free 6 weeks from debridement, being on antibiotics was not associated with treatment failure (adjusted hazard ratio [aHR] 0.71; 95% CI .48–1.07; P = .10). In a 12-week landmark analysis limited to 359 patients who were not on indefinite suppressive antibiotic therapy, treatment durations > 12 weeks did not significantly reduce the risk of failure (aHR 1.01; 95% CI .62–1.64; P = .99). Results were consistent in the clone-censor-weight sensitivity analysis (aHR 0.85; 95% CI .62–1.16; P = .30). Conclusions Prolonged antibiotic therapy was not associated with improved outcomes in early PSII managed with debridement and implant retention. These results support shorter, individualized antibiotic courses in patients with adequate surgical source control.
Pathogenic PF4 /Polyanion ELISA ‐Negative Antibodies in HIT
Kanack, Adam J. , Splinter, Noah P., Mauch, Emily, Gil, Morayma Reyes, Jasra, Sakshi , Goodwin, Andrew, Smock, Kristi J. , Ahmad, Hadiyah, Ashrani, Aneel A. , Robinson, Nathaniel L. , Jones, Curtis G., Pechauer, Shannon M., yttre, erin , Aster, Richard H. , Kohlhagen, Mindy , Leger, Rachel, Johns, Gretchen, Murray, David , Zhou, Lu, Wang, Demin, Wen, Renren , Chen, Dong, Pruthi, Rajiv K. , Padmanabhan, Anand , Wang, Demin , Zhou, Lu , Mauch, Emily E, Smock, Kristi J , Kohlhagen, Mindy C, Leger, Rachel R, Chen, Dong , Padmanabhan, Anand , Wang, Demin , Tefera, Leben T. , Gil, Morayma Reyes , Casanegra, Ana I. , Johns, Gretchen S., Zhou, Lu

Mayo Clinic

American Journal of Hematology | May 2, 2026 | Volume: 101 | Issue: 8 | Pages: 1790-1798

10.1002/ajh.70333 | PMID 42068120 Get It

ABSTRACT Background Platelet factor 4‐polyanion enzyme‐linked immunosorbent assays (ELISAs) are considered highly sensitive for diagnosing heparin‐induced thrombocytopenia (HIT), such that current practice guidelines recommend use of ELISA‐negative results to exclude HIT. Once HIT is ruled out, alternative, non‐heparin‐based anticoagulant treatments are ceased, and heparin reintroduction frequently occurs. Methods Antigen‐based and PF4‐dependent functional testing were used to study PF4/polyvinylsulfonate ELISA‐negative platelet‐activating antibodies in HIT‐suspected patients. Results Three patients with clinical presentations consistent with HIT tested negative in an ELISA using PF4‐polyvinylsulfonate (PF4/PVS), an antigenic target very commonly used for HIT antibody screening. All three patients demonstrated PF4‐dependent platelet activation in functional testing that was sensitive to blockade of platelet FcγRIIa receptors and inhibited by high concentrations of heparin, consistent with pathogenic HIT antibodies. Functional testing‐based screening of 500 ELISA‐negative patients identified three additional patients whose sera activated platelets in a PF4‐ and FcγRIIa‐dependent manner and had clinical histories consistent with HIT. Five of the six ELISA‐negative HIT patients were re‐exposed to heparin, which precipitated a decrease in platelet counts in all re‐exposed patients, and one patient developed a new thrombus. Conclusions Recognition of ELISA‐negative HIT is critical to avoid harm due to the cessation of alternative anticoagulation therapy and re‐exposure of these patients to heparin.
SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma
Uprety, Anusha , Judd, Chandler , Villella, Emily D , Keller, Rebecca , Wagner, Ryan, Robertson, Keith D. , Rodríguez‐Blanco, Jezabel , Barnoud, Thibaut , Mason, Frank M. , Ho, Thai H. , Wagner, Ryan T , de Cubas, Aguirre A , Ho, Thai , Robertson, Keith D , Wagner, Ryan T.

Mayo Clinic

Cancer Research | April 30, 2026 | Volume: 86 | Issue: 15 | Pages: 3838-3852

10.1158/0008-5472.can-25-3195 | PMID 42060867 Get It

Abstract SETD2 is frequently mutated or deleted in clear cell renal cell carcinoma (ccRCC). Loss of SETD2 could create synthetic lethal dependencies that confer therapeutic vulnerabilities. In this study, we demonstrated that SETD2 deficiency promotes cytoplasmic mitochondrial DNA (mtDNA) leakage, leading to basal activation of cGAS-STING inflammatory signaling and increased apoptotic priming. This inflammatory state upregulated the BH3-only protein NOXA, constrained myeloid cell leukemia 1 (MCL-1) function, and enforced a synthetic lethal dependency on the antiapoptotic protein BCL-xL. Pharmacologic inhibition of BCL-xL further amplified cGAS-STING signaling in SETD2-deficient cells through sublethal mitochondrial outer membrane permeabilization, resulting in increased mtDNA release and robust NOXA induction. Elevated NOXA neutralized the compensatory MCL-1–mediated survival signaling, triggering apoptosis. In contrast, SETD2-proficient ccRCC cells exhibited minimal cGAS-STING activation and failed to induce NOXA following BCL-xL inhibition, rendering them resistant. Genetic ablation of cGAS, STING, IRF3, or NOXA rescued sensitivity to BCL-xL inhibition, confirming that mtDNA-driven innate immune signaling is required for this dependency. In vivo, BCL-xL inhibition suppressed tumor growth and prolonged survival in SETD2-deficient xenograft models. Collectively, these findings establish a mechanistic link between SETD2 loss, mtDNA-driven innate immune activation, and enforced BCL-xL dependence in ccRCC, revealing a therapeutically targetable vulnerability in SETD2-deficient tumors. Significance: SETD2 deficiency, which is associated with worse prognosis in kidney cancer, promotes mitochondrial DNA-driven cGAS-STING signaling and NOXA-mediated apoptotic priming, creating a therapeutically targetable dependency on BCL-xL in kidney cancer.
Recurrent cross-reactivity between Candida tropicalis and Candida parapsilosis on the BIOFIRE FilmArray Blood Culture Identification 2 panel
Stevens, Ryan W, Wengenack, Nancy L. , Puumala, Emily , Wengenack, Nancy L , Stevens, Ryan W.

Mayo Clinic

Journal of Clinical Microbiology | April 30, 2026 | Volume: 64 | Issue: 6 | Pages: No page available

10.1128/jcm.00335-26 | PMID 42059605 Get It